Envoy Medical Beats Q3 Loss Estimates at $0.50/Share, Revenue Up 57%
COCH sits 94% above its 52-week low of $3.625.
Summary
Envoy Medical posted a Q3 adjusted loss of $0.50 per share, well better than the $0.67 consensus and a big improvement from the $3.40 loss a year ago. Revenue rose 57.1% to $66 thousand, though that fell short of the $86.67 thousand analysts expected. The net loss was $5.24 million, and the company ended the quarter with $14.6 million in cash — the same figures disclosed in this morning's 8-K. The cash balance is the number that matters: the last 10-Q flagged runway only through Q1 2027 with going-concern doubt, and this quarter's burn keeps that clock running. The 1-for-10 reverse split took effect October 26, so all per-share figures here are post-split. The stock closed at $7.12, and the median analyst target of $20.00 implies the Street is still pricing the PMA approval path rather than near-term financials.
At the time of this announcement, COCH was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.5M. The 52-week trading range was $3.63 to $9.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.